North America Intravenous Immunoglobulin Market Size and Forecasts (2020 – 2030)

North America Intravenous Immunoglobulin Market Size and Forecasts (2020 – 2030), Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (IgG, IgA, IgM, and Others), Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Idiopathic Thrombocytopenic Purpura, Multifocal Motor Neuropathy, Hypogammaglobulinemia, Guillain-Barre Syndrome, Specific Antibody Deficiency, Inflammatory Myopathies, Myasthenia Gravis, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Country (US, Canada, and Mexico)

Send Enquiry
Item ID: TIPRE00030117 Category: Tags: , ,

$2,100$3,500

Description

The North America intravenous immunoglobulin market size was valued at US$ 5.042 Bn in 2022 and is expected to reach US$ 8.747 Bn by 2030; it is estimated to record a CAGR of 7.1% from 2022 to 2030. The North America intravenous immunoglobulin market growth is primarily driven by increase in use of immunoglobulins and rising prevalence of immunodeficiency diseases

New Product Launches and Approvals Opportunity for Growth of Intravenous Immunoglobulin Market

In recent years, there have been various developments in the intravenous immunoglobulin market in North America. Market players have been launching new products and seeking regulatory approvals for their offerings. In April 2023, Takeda Pharmaceutical Company Limited, an R&D-driven biopharmaceutical leader, received a supplemental Biologics License Application (sBLA) approval from the US Food and Drug Administration (FDA) to expand the use of HYQVIA to treat primary immunodeficiencies (PI) in children belonging to the age group of 2–16 years. Only HYQVIA’s subcutaneous immune globulin (ScIG) infusion allows for monthly administration. In 2022, Health Canada approved HyQvia, a new Immunoglobulin (IG) treatment for Canadians with immune deficiencies. In February 2021, Pfizer Inc. received an sBLA approval for PANZYGA (10% liquid intravenous immunoglobulin preparation) to treat chronic inflammatory demyelinating polyneuropathy (CIDP)

Type-Based Insights

The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030.

Application-Based Insights

Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030.

Distribution Channel -Based Insights

Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030.

End User – Based Insights

Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030.

Patients with autoimmune diseases are treated with intravenous immunoglobulins. Autoimmune diseases are conditions wherein the immune system accidentally attacks its own tissues or cells. Chronic inflammation, and organ and system damage result from this aberrant immune reaction against healthy cells. Fatigue, joint pain, muscle weakness, skin rashes, and neurological disturbances are a few of the typical signs and symptoms of autoimmune diseases. Symptoms of autoimmune diseases such as Guillain-Barré syndrome (GBS), myasthenia gravis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (LE), and immune thrombocytopenia (ITP) can be alleviated with the IVIG therapy. Benefits of this therapy include the rapid relief of symptoms and long-lasting effects, leading to improved quality of life among patients.

According to the Intermountain Healthcare, autoimmune and immune-mediated diseases and conditions affect 23.5–50 million Americans. According to the Centers for Disease Control and Prevention, rheumatoid arthritis (RA) is the most prevalent type of autoimmune arthritis, and 1 in 4 adults in the US has arthritis. As per the Myasthenia Gravis Foundation of America, Inc., the prevalence of myasthenia gravis (MG) is estimated at 14–20 per 100,000 of the US population. In Canada, the incidence of MG is estimated to be 23 per 1 million person-years, with a prevalence of 263 per 1 million people, and the numbers have been stable over the past few decades.

Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market

Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.

Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.

A few of the major primary and secondary sources referred to while preparing the report on the North America intravenous immunoglobulin market are the Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

According to our latest study on ” North America Intravenous Immunoglobulin Market Size and Forecast to 2030 – Regional Analysis – by Type, Application, Distribution Channel, and End User,” the North America intravenous immunoglobulin market size was valued at US$ 5.042 billion in 2022 and is expected to reach US$ 8.747 billion by 2030. It is estimated to register a CAGR of 7.1% during 2022–2030. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. The deficiency of immunoglobulin requires the external administration of immunoglobulin and is known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIg is manufactured from human plasma. It contains antibodies and is used to treat many immunologic, haematologic, and neurologic illnesses.

Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is on the rise with the surging use of these antibodies for treating various conditions

Table: Common Use and Dosing for Intravenous Immunoglobulins

Disease/Medical Condition FDA Approval Status Goal of Therapy

B-Cell Chronic Lymphocytic Leukemia (CLL) Yes Prevention of bacterial infections due to hypogammaglobinemia

Bone Marrow Transplantation Complications Yes Prevention of infections, pneumonitis, and acute graft-versus-host disease (GVHD) following bone marrow transplantation

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Yes Improvements in patients suffering from neuromuscular disability and impairment, and maintenance therapy to prevent relapse

HIV Infection Yes Reduction of serious bacterial infections in pediatric patients infected with HIV

Idiopathic Thrombocytopenic Purpura (ITP, CITP) Yes Increase platelet count in ITP to prevent or control bleeding

Kawasaki Disease Yes Prevention of coronary artery aneurism associated with Kawasaki disease

Multifocal Motor Neuropathy (MMN) Yes Modulation of immune-inflammatory condition, improvement of muscle strength, and management of disability in adult patients

Primary Immunodeficiency Disease (PIDD) Yes Protection against frequent and/or severe infections (bacterial and viral)

Source: Academy of Managed Care Pharmacy

Leading players in the intravenous immunoglobulin market have multiple projects and many biological products in pipelines based on proprietary technologies. Evolve Biologics plans to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. It completed the Phase III clinical trial for its IVIG candidate in February 2021, and it intends to develop a portfolio of this product candidate. Similarly, Biotest, offering plasma protein products and biotherapeutic drugs, is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation from human plasma to treat immunodeficiencies and autoimmune diseases through intravenous administration. In September 2020, the company completed its Phase III trial investigating the administration of IgG Next Generation for treating patients with PIDs. In May 2020, the US Food and Drug Administration (FDA) approved Octapharma’s Investigational New Drug (IND) application to initiate a Phase 3 trial of Octagam (immune globulin intravenous) to treat patients suffering from COVID-19, with severe disease progression.

Companies are investing in scientific and technical excellence to develop and introduce new IVIG therapies against immunodeficiencies. Thus, a strong pipeline of IVIG candidates would lead to a significant growth trend in the North America intravenous immunoglobulin market in the future.

Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the key players operating in the global North America intravenous immunoglobulin market.

The report segments the North America intravenous immunoglobulin market as follows:

The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030. Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030. Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030. Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030. Based on country, the North America intravenous immunoglobulin market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share. The intravenous immunoglobulins market in Canada is expected to grow at the highest CAGR during 2022–2030.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific PEST Analysis
5. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Increasing Burden of Periodontal Diseases and Oral Cancer
5.1.2 Strategic Developments by Market Players
5.2 Market Restraints
5.2.1 High Cost of Products & Procedures and Delays in Dental Check-ups
5.3 Market Opportunities
5.3.1 Technological Developments in Dentistry
5.4 Future Trends
5.4.1 Digitization of Dentistry with CAD/CAM Technology
5.5 Impact Analysis:
6. Dental Bone Graft Substitute and Barrier Membrane Market – Asia Pacific Market Analysis
6.1 Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Revenue (US$ Mn), 2022 – 2030
7. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 – by Product
7.1 Overview
7.2 Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Revenue Share, by Product 2022 & 2030 (%)
7.3 Dental Bone Graft Substitute
7.3.1 Overview
7.3.2 Dental Bone Graft Substitute: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.3 Allograft
7.3.3.1 Overview
7.3.3.2 Allograft: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.4 Xenograft
7.3.4.1 Overview
7.3.4.2 Xenograft: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.5 Synthetic Bone Graft
7.3.5.1 Overview
7.3.5.2 Synthetic Bone Graft: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.6 Autografts
7.3.6.1 Overview
7.3.6.2 Autografts: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.7 Alloplasts
7.3.7.1 Overview
7.3.7.2 Alloplasts: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.8 Demineralized Bone Matrix (DBM)- Allograft
7.3.8.1 Overview
7.3.8.2 Demineralized Bone Matrix (DBM)- Allograft: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.9 Others
7.3.9.1 Overview
7.3.9.2 Others: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Dental Barrier Membrane
7.4.1 Overview
7.4.2 Dental Barrier Membrane: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.4.3 Resorbable Membrane
7.4.3.1 Overview
7.4.3.2 Resorbable Membrane: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.4.4 Non-Resorbable Membrane
7.4.4.1 Overview
7.4.4.2 Non-Resorbable Membrane: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 – by Procedures
8.1 Overview
8.2 Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Revenue Share, by Procedures 2022 & 2030 (%)
8.3 Guided Bone Regeneration Procedures (GBR)
8.3.1 Overview
8.3.2 Guided Bone Regeneration Procedures (GBR): Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Guided Tissue Regeneration Procedures (GTR)
8.4.1 Overview
8.4.2 Guided Tissue Regeneration Procedures (GTR): Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Sinus-lift Procedures and Ridge-split Procedures
8.5.1 Overview
8.5.2 Sinus-lift Procedures and Ridge-split Procedures: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Alveolar Ridge Preservation (ARP)
8.6.1 Overview
8.6.2 Alveolar Ridge Preservation (ARP): Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Block-graft Procedures
8.7.1 Overview
8.7.2 Block-graft Procedures: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Periodontal Regeneration Procedures
8.8.1 Overview
8.8.2 Periodontal Regeneration Procedures: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Socket Preservation
8.9.1 Overview
8.9.2 Socket Preservation: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.10 Others
8.10.1 Overview
8.10.2 Others: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Dental Clinics
9.4.1 Overview
9.4.2 Dental Clinics: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market – Country Analysis
10.1 Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, Revenue And Forecast to 2030
10.1.1 Overview
10.1.1.1 Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market by Country
10.1.1.2 China
10.1.1.2.1 Overview
10.1.1.2.2 China Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.3 China Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.2.3.1 China Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.2.3.2 China Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.2.4 China Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.2.5 China Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.3 Japan
10.1.1.3.1 Overview
10.1.1.3.2 Japan Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.3 Japan Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.3.3.1 Japan Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.3.3.2 Japan Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.3.4 Japan Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.3.5 Japan Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.4 India
10.1.1.4.1 Overview
10.1.1.4.2 India Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.3 India Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.4.3.1 India Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.4.3.2 India Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.4.4 India Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.4.5 India Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.5 Australia
10.1.1.5.1 Overview
10.1.1.5.2 Australia Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.5.3 Australia Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.5.3.1 Australia Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.5.3.2 Australia Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.5.4 Australia Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.5.5 Australia Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.6 South Korea
10.1.1.6.1 Overview
10.1.1.6.2 South Korea Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.6.3 South Korea Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.6.3.1 South Korea Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.6.3.2 South Korea Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.6.4 South Korea Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.6.5 South Korea Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.7 Rest of Asia Pacific
10.1.1.7.1 Overview
10.1.1.7.2 Rest of Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.7.3 Rest of Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.7.3.1 Rest of Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.7.3.2 Rest of Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.7.4 Rest of Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.7.5 Rest of Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, by End User
11. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market Industry Landscape
11.1 Overview
11.2 Growth Strategies in Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Asia Pacific Dental Bone Graft Substitute and Barrier Membrane Market, Key Company Profiles
12.1 Geistlich Pharma AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Medtronic Plc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Dentsply Sirona Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ZimVie Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Regenity Biosciences Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Neoss UK & Ireland Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Institut Straumann AG
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Intravenous Immunoglobulin Market Segmentation
Table 2. North America Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 6. US Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 8. US Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 9. US Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Intravenous Immunoglobulin Market, by Type– Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Intravenous Immunoglobulin Market, by Type– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 18. Recent Inorganic Growth Strategies in the North America Intravenous Immunoglobulin Market
Table 19. Recent Organic Growth Strategies in North America Intravenous Immunoglobulin Market
Table 20. Glossary of Terms, North America Intravenous Immunoglobulin Market

LIST OF FIGURES

Figure 1. Intravenous Immunoglobulin Market Segmentation, By Geography
Figure 2. Global – PEST Analysis
Figure 3. Intravenous Immunoglobulin Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Intravenous Immunoglobulin Market Revenue (US$ Mn), 2022 – 2030
Figure 6. Intravenous Immunoglobulin Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 7. IgG: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. IgA: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. IgM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Intravenous Immunoglobulin Market Revenue Share, by Application, 2022 & 2030 (%)
Figure 12. Immunodeficiency Diseases: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Chronic Inflammatory Demyelinating Polyneuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Hypogammaglobulinemia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Guillain-Barre Syndrome: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Specific Antibody Deficiency: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Inflammatory Myopathies: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Myasthenia Gravis: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Intravenous Immunoglobulin Market Revenue Share, by Route of Administration, 2022 & 2030 (%)
Figure 23. Hospital Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Retail Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Intravenous Immunoglobulin Market Revenue Share, Species, 2022 & 2030 (%)
Figure 27. Hospitals: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Specialty Clinics: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. North America: Intravenous Immunoglobulin Market, by Key Country – Revenue (2022) (US$ Million)
Figure 31. North America Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. North America Intravenous Immunoglobulin Market, By Key Countries, 2022 and 2030 (%)
Figure 33. US Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Canada Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Mexico Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Growth Strategies in North America Intravenous Immunoglobulin Market

The List of Companies – North America Intravenous Immunoglobulin Market
– Takeda Pharmaceutical Co Ltd
– Grifols SA
– Pfizer Inc
– ADMA Biologics, Inc
– Bio Products Laboratory Ltd
– Octapharma AG
– Kedrion SpA
– CSL Ltd
– LFB Group
– Prothya Biosolutions B.V

Reviews

There are no reviews yet.

Be the first to review “North America Intravenous Immunoglobulin Market Size and Forecasts (2020 – 2030)”